Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
Dawood
Shaheenah
S
Department of Medical Oncology, Dubai Hospital, United Arab Emirates.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D015973:Gene Expression Regulation, Leukemic; D015972:Gene Expression Regulation, Neoplastic; D014644:Genetic Variation; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D013629:Tamoxifen / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043823:Taxoids; D013629:Tamoxifen; D005472:Fluorouracil